A GoodRx guide on easing common GLP-1 symptoms, separating the support options that seem to work from the ones that fall short.
Recap by typeshit. Full story at GoodRx.
She walks through the phase 3 data, including knee osteoarthritis results, and explains why she calls online reta vials a gamble.
In a Healio Eye-Mail brief, she gives her view on a review of a possible link between GLP-1 medications and NAION, a type of optic nerve damage.
Retatrutide is still in clinical trials, yet people are discussing using it online. A new analysis takes a first systematic look at the side effects they describe.
The Atlanta Journal-Constitution looks at how an unapproved weight loss drug is being sold through an underground market across Georgia.
Novo Nordisk India's managing director Vikrant Shrotriya told Financial Express he sees steady growth even as cheaper generics move in, per Investseekers.
A podcast clip argues GLP-1 drugs need longer-term thinking than a quick cosmetic fix, and pushes viewers to comment for the full episode.
Loading…